<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110983">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948765</url>
  </required_header>
  <id_info>
    <org_study_id>SR022013</org_study_id>
    <nct_id>NCT01948765</nct_id>
  </id_info>
  <brief_title>Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery.</brief_title>
  <official_title>Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery:a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium:  Federal Agency for Medicinal &amp; Health Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that the application of 30% xenon as an adjuvant to general
      anesthesia with a target-controlled infusion of propofol is superior to general anesthesia
      with propofol alone with respect to hemodynamic stability.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>intraoperative haemodynamic stability</measure>
    <time_frame>intra-operative</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Haemodynamic stability as assessed by the individual intraoperative noradrenaline consumption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE (major adverse cardiac and cerebral events)</measure>
    <time_frame>up to six months postoperative</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Death from any cause, perioperative life-threatening cardiac arrhythmias, perioperative myocardial infarction, requirement of surgical revisions at the coronary vessels, postoperative coronary angioplasty and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebrovascular accident not included in MACCE</measure>
    <time_frame>up to six months postoperative</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>cerebrovascular accident not included in MACCE (TIA, reversible ischaemic neurologic deficit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative renal function</measure>
    <time_frame>up to five days postoperative</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>postoperative renal function as assessed by serum creatinine and BUN levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>requirement for blood(product) transfusion</measure>
    <time_frame>up to five days postoperative</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>requirement for blood(product) transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 10 days.</time_frame>
    <safety_issue>No</safety_issue>
    <description>requirement for blood(product) transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of postoperative critical illness</measure>
    <time_frame>up to five days postoperative</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Severity of postoperative critical illness as indicated by the new simplified acute physiology score (SAPS II), SOFA and APACHE-II score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and duration of postoperative delirium</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expectged average of 10 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>incidence and duration of postoperative delirium assessed with the Confusion Assessment Method (CAM-ICU), to be assessed in combination with the Mini Mental State Examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of further AE, SAE and SUSAR</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 10 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Xenon  and propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenon and propofol</intervention_name>
    <description>xenon 30% in oxygen as an adjuvant to propofol target  controlled infusion (target of 0.5-1.5µg/ml)</description>
    <arm_group_label>Xenon  and propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>propofol target controlled infusion (target 1.5-2.5µg/ml)</description>
    <arm_group_label>propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with coronary artery disease scheduled for elective OPCAB-surgery

          -  patients willing and able to complete the requirements of this study

          -  Ejection fraction &gt;30%

        Exclusion Criteria:

          -  Lack of informed consent

          -  age &lt; 18 years

          -  COPD GOLD &gt;II

          -  Renal dysfunction defined as serum-creatinine &gt;1.5mg/dl

          -  acute coronary syndrome during the last 24 hours; haemodynamic    instability,
             requirement of inotropic support

          -  single vessel grafting

          -  disabling neuropsychiatric disorders (severe dementia, Alzheimer's disease,
             schizophrenia, depression, low preoperative cognitive state (MMSE at baseline &lt;25),
             history of stroke with residuals, increased intracranial pressure

          -  Hypersensitivity to the study medication

          -  Presumed uncooperativeness or legal incapacity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>August 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>prof Dr Steffen Rex</investigator_full_name>
    <investigator_title>PhD, MD</investigator_title>
  </responsible_party>
  <keyword>xenon anesthesia</keyword>
  <keyword>Off-pump coronary artery bypass graft surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Xenon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
